John Burton Joins Power3 as Chief Accountant; Sciona Taps Roy Whitfield as Chairman of Advisory Board; Tom Daniel, Mark Carthy to Leave Solexa Board; John Schneider Takes VP of Marketing Spot at Vitra Bioscience; and Others

John Burton has become chief accounting officer and controller of Power3 Medical Products, the proteomics company based in The Woodlands, Texas, said yesterday. He replaces Michael Rosinski, who resigned as chief financial officer "to pursue other business opportunities," according to the company. Burtoncomes to Power3 from Affiniscape, an Austin-based web site developer, where he was chief financial officer. He holds an MBA and a BBA from the University of Texas at Austin. Power3 said today that it has been delisted from the over-the-counter bulletin board.

Roy Whitfield has been appointed as a director and chairman of the science and business advisory board of Sciona, the Boulder, Colo.-based company said on Tuesday. Most recently, Whitfield was chief executive officer and chairman of Incyte.

Tom Daniel and Mark Carthy will not stand for re-election to the board of directors of Solexa at the company's June 7 annual stockholders' meeting, Solexa said last week in an SEC filing. The two directors informed the board of their decisions on June 3, the company said. Daniel is a founder and partner of Life Science Capital, an investment management business. He has an MBA from Harvard Business School and an undergraduate degree in biological sciences from the Universityof Oxford. Carthy is a venture partner at Oxford Bioscience Partners. He holds an MBA from Harvard Business School, an MS in chemical engineering from the University of Missouri and a BE in chemical engineering from University College Dublin in Ireland.

John Schneider has become vice president of marketing and business development of Vitra Bioscience, Cell-Based Assay News, a GenomeWeb newsletter, reported this week. Prior to joining Vitra, Schneider was R&D director and vice president of marketing and business development at Molecular Dynamics and Amersham Biosciences, both of which were acquired by GE Healthcare last year.

Peter Barrett has become chairman of the board of directors of Momenta Pharmaceuticals, the company said on Monday. Barrett, who takes over the post from Alan Crane, who will remain chief executive officer and president, has been a director since May 2003. He is a senior partner at Atlas Venture. Barrett used to be executive vice president and chief business officer of Celera Genomics. Prior to that, he held senior management positions at Applera, most recently vice president for corporate planning and business development.

Stark Thompson has been appointed to the board of directors of Luminex, the company said on Tuesday. Until his retirement in 2000, he was president, chief executive officer, and director of Life Technologies. Thompson holds PhD and MS degrees in physiological chemistry from Ohio State University and a BS degree from MuskingumCollege. He is currently also a director of Gene Logic.

Russell Allen has joined Ceragenix as vice president of corporate development, the Denver-based company said yesterday. Prior to this, he was senior vice president of corporate development for Cellular Genomics. Allen holds an MBA from the Harvard Graduate School of Business Administration and a BA from AmherstCollege.

Mary Tanner has been re-elected to the supervisory board of Evotec OAI, while Hubert Birner, Peter Fellner, and Alfred Oberholz have been appointed to the supervisory board, the company said last week.

Frank Brown and Russell Schwartz have received the Presidential Early Career Award for Scientists and Engineers, the National Science Foundation said on Tuesday. Brown, an assistant professor of chemistry and biochemistry at the Universityof California, Santa Barbara, is developing new computational algorithms to investigate cellular phenomena. Schwartz, an assistant professor of biological sciences at Carnegie Mellon University, is developing computational methods to describe and simulate the self-assembly of biological structures and cell components.

Ronald Lindsay has joined the board of directors of ArQule, the Woburn, Mass.-based company said on Tuesday. He currently operates Milestone Consulting, a biotechnology consulting enterprise, and is a director of Sequenom. Lindsay holds a PhD in biochemistry from the Universityof Calgary and a BSc in chemistry from the Universityof Glasgow.

Chris Goodnow, a professor of immunology at the Australian National University, has received the Commonwealth Health Minister's Award for Excellence in Health and Medical Research from the Australian government for his research in molecular genetics, ANU said last week. He is also the director of the Australian Phenomics Facility and head of the Medical Genome Center at the JohnCurtinSchoolof Medical Research.

Thomas Adams has joined the board of directors of Iris International, the maker of automated urinalysis systems said last week. He is currently chairman and chief executive officer of Leucadia Technologies. Adamsis the founder and chairman emeritus of Genta, and the co-founder and former chief executive officer of Gen-Probe.

Richard Schifreen has joined Mirus Bio as the company's vice president of research products, the company said earlier this month. He joins Mirus from Promega, where he was as director of technology and business development. He is also a faculty member of the University of Wisconsin-Madison in the masters of science in biotechnology program. Schifreen holds a PhD in analytical chemistry from the Universityof Georgia.

Mirus also said last week that it has appointed Joseph Williams as vice president of finance and administration. Williams was previously vice president of finance and administration at Reliant Technologies, a medical laser company. Williams holds a bachelor's degree in accounting from Southwest Texas State University.

William Gerber and Frank Jellinek have joined the board of directors of Nanogen, while Val Buonaiuto has retired from the board, the San Diego-based company said last week. Gerber is a partner at Bay City Capital, a life sciences investment fund. Most recently, he was president and chief executive officer of Epoch BioSciences, which merged with Nanogen in late 2004.

Jellinek is currently chairman emeritus of Fisher Scientific International and was formerly the president, chief executive officer, and a director of Apogent Technologies until it was acquired by Fisher in 2004.

John Reed has joined the board of directors of Pharmion, the Boulder, Colo.-based company said earlier this month. He is the president and chief executive officer of the Burnham Institute in La Jolla, Calif.Reed is also a director of Stratagene. He holds MD and PhD degrees from the University of Pennsylvania School of Medicine.

Jeff Warren has become the first non-executive director of Oxford Genome Sciences, the company said last week. In the past, he was the chief financial officer of Bristol and West Building Society and later the chief executive officer of Bristoland West.

Gary Van Berkel received the Biemann Medal of the American Society of Mass Spectrometry at the society's meeting last week for his contributions to the mass spec field. He is a group leader of the organic and biological mass spectrometry group at Oak RidgeNational Laboratory's chemical sciences division. Van Berkel was honored for his work to better understand the electrochemical nature of the electrospray ion source. He holds a doctorate in analytical chemistry from Washington State University and a bachelor's degree in chemistry from Lawrence University in Wisconsin.

Georg Casari has joined Oridis Biomed as chief information officer, the Graz, Austria-based company said last week. Previously, he was vice president of informatics at Cellzome and senior vice president of life science informatics research at Lion Bioscience.

Moses Mares has joined Acacia Technologies as vice president of business development and will join the company's patent acquisition team, Newport Beach, Calif.-based Acacia said last week. Most recently, he was a senior corporate counsel with Siebel Systems. Mares, a registered patent attorney, holds an MS in chemical engineering from the University of Texas Austin, an MS in electrical and computer engineering from the University of California San Diego, a JD degree from Santa Clara University, and a BS degree in chemical engineering from the California Institute of Technology.

James Burns has joined the board of directors of Ciphergen Biosystems, the company said last week. He is the president and chief executive officer of EntreMed. Burns holds an MBA degree from DePaul University as well as MS and BS degrees in biological sciences from the Universityof Illinois.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.